4D Molecular Therapeutics (4DMT) Stock

4dmoleculartherapeutics.comHealthcare / BioTech & PharmaFounded: 2013Funding to Date: $109MM

4DMT is a biotechnology company focused on pioneering the development of precision gene therapies based on proprietary AAV vectors.

Register To Buy and Sell Shares

For more details on financing and valuation for 4D Molecular Therapeutics (4DMT), register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access 4D Molecular Therapeutics (4DMT)’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like 4D Molecular Therapeutics (4DMT).

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

David Kirn MD
Chief Executive Officer, Chairman & Co-Founder
Melissa Kotterman Ph.D
Vice President, Discovery & Engineering & Co-Founder
August Moretti JD
Chief Financial Officer
Fred Kamal Ph.D
Chief Technology Officer
Peter Francis MD
Chief Medical Officer
Theresa Janke
Co-Founder & Chief Operating Officer
Leisa Johnson
Vice President, Pre-Clinical R&D, Pharmacology & Toxicology Program Leader, Lung Therapeutic Area
David Schaffer Ph.D
Co-Founder, Chief Scientific Advisor & Board Member

Board Members

Charles Theuer MD
Deborah Marshall JD
Sidley Austin
Margi McLaughlin Ph.D
David Schaeffer Ph.D
Hoyoung Huh Ph.D
David Kirn MD
Jacob Chacko MD
Tony Yao Ph.D
ArrowMark Partners
Updated on: Dec 6, 2023


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.